Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine.
OBJECTIVE
Ototoxicity often limits the dose of desferrioxamine (DFO) tolerated by patients who are transfusion dependent. Current recommendations advise doses of < 50 mg/kg/day after early reports noted higher rates of oxotoxicity with increasing doses. There have been no follow-up studies to determine the effect of this recommendation on oxotoxicity and iron overload.


METHODS
We followed 28 patients who were chronically chelated with serial audiograms over a 5-year period. Patients with and without oxotoxicity were compared with respect to age, disease, DFO dose, peak DFO dose, length of DFO therapy, ferritin, and therapeutic index.


RESULTS
Eight of the 28 patients (29%) had an abnormal audiogram during threshold testing. Two patients had two separate episodes with hearing deficit. Nine of the 10 episodes were high-frequency losses, with seven being moderate and three mild. All deficits were rapidly reversible with DFO dose reduction. No significant differences were found between the affected and unaffected groups with respect to age, DFO dose or duration, ferritin, or therapeutic index. Numbers of affected patients were small, but patients with SCD differed from patients with thalassemia in that they developed ototoxicity earlier and with lower doses of DFO and lower therapeutic indexes.


CONCLUSIONS
Despite DFO doses usually felt to be low risk for ototoxicity, we found a high rate of ototoxicity in our patients who we've chronically chelated. No variables were identified that reliably predicted ototoxicity. We stress the need for regular audiological exams and feel no dose of DFO is "safe" from the development of ototoxicity.
Styles
L A
LA
Department of Hematology/Oncology, Children's Hospital Oakland 94609, USA.
Vichinsky
E P
EP
D000293:Adolescent; D000328:Adult; D001299:Audiometry; D001309:Auditory Threshold; D015913:Chelation Therapy / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005293:Ferritins / Q000097:blood; D006309:Hearing / Q000187:drug effects*; D006453:Hemoglobinopathies / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D017262:Siderophores / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D017262:Siderophores; D005293:Ferritins; D003676:Deferoxamine